PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.013
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

OA05.07 IMpower132: PFS and Safety Results With 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Study: Atezolizumab Improves Survival in SCLC

Cancer Discovery
Oncology
2018English

First-Line Atezolizumab OK'd for SCLC

Cancer Discovery
Oncology
2019English

SCLC – Vergleichbare Wirksamkeit Von Cisplatin Und Carboplatin

Pneumologie
MedicinePulmonaryRespiratory Medicine
2015English

Pharmacokinetics of Carboplatin and Etoposide in a Hemodialysis Patient With Small Cell Lung Carcinoma.

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
1996English

Carboplatin Plus Etoposide Induced a Complete Response in a Hemodialysis Patient With Limited Stage Small Cell Lung Cancer–a Case Report and Literature Review–

Nihon Toseki Igakkai Zasshi
2017English

P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Addition of Lenalidomide to Rituximab, Ifosfamide, Carboplatin, Etoposide (RICER) in First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

British Journal of Haematology
Hematology
2014English

P1.12-11 2010 – 2015 Extensive Stage SCLC Diagnoses in a Canadian Institution: Baseline Characteristics That Impact on the Overall Survival

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy